Literature DB >> 22238300

Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells.

Yali Zhu1, Nil Celebi Cherukuri, Jamie N Jackel, Zetang Wu, Monica Crary, Kenneth J Buckley, David M Bisaro, Deborah S Parris.   

Abstract

Ebola virus (EBOV) causes a lethal hemorrhagic fever for which there is no approved effective treatment or prevention strategy. EBOV VP35 is a virulence factor that blocks innate antiviral host responses, including the induction of and response to alpha/beta interferon. VP35 is also an RNA silencing suppressor (RSS). By inhibiting microRNA-directed silencing, mammalian virus RSSs have the capacity to alter the cellular environment to benefit replication. A reporter gene containing specific microRNA target sequences was used to demonstrate that prior expression of wild-type VP35 was able to block establishment of microRNA silencing in mammalian cells. In addition, wild-type VP35 C-terminal domain (CTD) protein fusions were shown to bind small interfering RNA (siRNA). Analysis of mutant proteins demonstrated that reporter activity in RSS assays did not correlate with their ability to antagonize double-stranded RNA (dsRNA)-activated protein kinase R (PKR) or bind siRNA. The results suggest that enhanced reporter activity in the presence of VP35 is a composite of nonspecific translational enhancement and silencing suppression. Moreover, most of the specific RSS activity in mammalian cells is RNA binding independent, consistent with VP35's proposed role in sequestering one or more silencing complex proteins. To examine RSS activity in a system without interferon, VP35 was tested in well-characterized plant silencing suppression assays. VP35 was shown to possess potent plant RSS activity, and the activities of mutant proteins correlated strongly, but not exclusively, with RNA binding ability. The results suggest the importance of VP35-protein interactions in blocking silencing in a system (mammalian) that cannot amplify dsRNA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238300      PMCID: PMC3302343          DOI: 10.1128/JVI.05741-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

2.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

Review 3.  The diversity of RNA silencing pathways in plants.

Authors:  Peter Brodersen; Olivier Voinnet
Journal:  Trends Genet       Date:  2006-03-29       Impact factor: 11.639

4.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

Review 5.  A call to arms: coevolution of animal viruses and host innate immune responses.

Authors:  Joao T Marques; Richard W Carthew
Journal:  Trends Genet       Date:  2007-04-27       Impact factor: 11.639

6.  Adenosine kinase inhibition and suppression of RNA silencing by geminivirus AL2 and L2 proteins.

Authors:  Hui Wang; Kenneth J Buckley; Xiaojuan Yang; R Cody Buchmann; David M Bisaro
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

8.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  Herpes simplex virus type 1 suppresses RNA-induced gene silencing in mammalian cells.

Authors:  Zetang Wu; Yali Zhu; David M Bisaro; Deborah S Parris
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

10.  Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.

Authors:  Tsung-Hsien Chang; Toru Kubota; Mayumi Matsuoka; Steven Jones; Steven B Bradfute; Mike Bray; Keiko Ozato
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

View more
  14 in total

1.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 2.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

3.  Ebola Virus Produces Discrete Small Noncoding RNAs Independently of the Host MicroRNA Pathway Which Lack RNA Interference Activity in Bat and Human Cells.

Authors:  Abhishek N Prasad; Adam J Ronk; Steven G Widen; Thomas G Wood; Christopher F Basler; Alexander Bukreyev
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 4.  Camouflage and misdirection: the full-on assault of ebola virus disease.

Authors:  John Misasi; Nancy J Sullivan
Journal:  Cell       Date:  2014-10-16       Impact factor: 41.582

5.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

6.  Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome.

Authors:  Priya Luthra; Parameshwaran Ramanan; Chad E Mire; Carla Weisend; Yoshimi Tsuda; Benjamin Yen; Gai Liu; Daisy W Leung; Thomas W Geisbert; Hideki Ebihara; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Host Microbe       Date:  2013-07-17       Impact factor: 21.023

7.  Conservation of Structure and Immune Antagonist Functions of Filoviral VP35 Homologs Present in Microbat Genomes.

Authors:  Megan R Edwards; Hejun Liu; Reed S Shabman; Garrett M Ginell; Priya Luthra; Parmeshwaran Ramanan; Lisa J Keefe; Bernd Köllner; Gaya K Amarasinghe; Derek J Taylor; Daisy W Leung; Christopher F Basler
Journal:  Cell Rep       Date:  2018-07-24       Impact factor: 9.423

8.  Did silencing suppression counter-defensive strategy contribute to origin and evolution of the triple gene block coding for plant virus movement proteins?

Authors:  Sergey Y Morozov; Andrey G Solovyev
Journal:  Front Plant Sci       Date:  2012-07-06       Impact factor: 5.753

Review 9.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

10.  The VP3 factor from viruses of Birnaviridae family suppresses RNA silencing by binding both long and small RNA duplexes.

Authors:  Adrian Valli; Idoia Busnadiego; Varvara Maliogka; Diego Ferrero; José R Castón; José Francisco Rodríguez; Juan Antonio García
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.